✦ LIBER ✦

CYP2C19*2predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment

✍ Scribed by K. Beelen, M. Opdam, T. M. Severson, R. H. T. Koornstra, A. D. Vincent, M. Hauptmann, R. H. N. van Schaik, E. M. J. J. Berns, J. B. Vermorken, P. J. van Diest, S. C. Linn…show all 11hide

Book ID: 120963247
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 263 KB
Volume: 139
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-013-2568-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1405 POSTER DISCUSSION Cyp2C19*2 Polymor

1405 POSTER DISCUSSION Cyp2C19*2 Polymorphism Predicts Benefit of Adjuvant Tamoxifen in ER Positive Postmenopausal Breast Cancer Patients

✍ K. Beelen; R. Koornstra; M. Opdam; T. Severson; A. Vincent; R.J. van Diest; S. L 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Phosphorylated p-70S6K predicts tamoxife

Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment

✍ Beelen, Karin; Opdam, Mark; Severson, Tesa M; Koornstra, Rutger HT; Vincent, And 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 282 KB

Breast Cancer Treatment Outcome With Adj

Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes

✍ Stearns, V. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Adjuvant cyclic Tamoxifen and Megestrol

Adjuvant cyclic Tamoxifen and Megestrol acetate treatment in postmenopausal breast cancer patients – Longterm follow-up

✍ H.E. Fjøsne; A.-B. Jacobsen; S. Lundgren 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 225 KB

Phase III randomized adjuvant study of t

Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in hormone-responsive postmenopausal breast cancer patients (National Surgical Adjuvant Study of Breast Cancer [NSAS BC] 03)

✍ Y. Takatsuka; T. Aihara 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 204 KB

Genetic polymorphisms of CYP2D6*10 and C

Genetic polymorphisms of CYP2D6*10 and CYP2C19*2, *3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

✍ Matthew Goetz; Vera Suman 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 56 KB 👁 1 views

The study by Okishiro et al 1 concludes that the cytochrome P450 (CYP) genotype CYP2D6\*10/\*10 is unlikely to have a clinically significant impact on prognosis in women with breast cancer who receive adjuvant tamoxifen. However, several aspects of the study by Okishiro et al call their conclusions